Teacher Retirement System of Texas Sells 3,540 Shares of AbbVie Inc. $ABBV

Teacher Retirement System of Texas cut its position in AbbVie Inc. (NYSE:ABBV) by 0.6% in the third quarter, HoldingsChannel.com reports. The firm owned 574,951 shares of the company’s stock after selling 3,540 shares during the quarter. AbbVie comprises about 0.5% of Teacher Retirement System of Texas’ investment portfolio, making the stock its 22nd biggest holding. Teacher Retirement System of Texas’ holdings in AbbVie were worth $133,124,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Kingdom Financial Group LLC. bought a new position in shares of AbbVie in the third quarter worth about $209,000. Northstar Asset Management Inc. purchased a new position in AbbVie in the 3rd quarter worth approximately $259,000. Coign Capital Advisors LLC bought a new position in AbbVie in the 3rd quarter worth approximately $744,000. Parkside Financial Bank & Trust grew its holdings in AbbVie by 2.4% during the 3rd quarter. Parkside Financial Bank & Trust now owns 29,431 shares of the company’s stock valued at $6,814,000 after buying an additional 676 shares in the last quarter. Finally, Facet Wealth Inc. lifted its holdings in shares of AbbVie by 6.1% in the third quarter. Facet Wealth Inc. now owns 3,783 shares of the company’s stock worth $876,000 after buying an additional 216 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on ABBV shares. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Berenberg Bank set a $275.00 price objective on AbbVie in a research report on Tuesday. Guggenheim lifted their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research note on Thursday, January 15th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $248.11.

AbbVie Trading Up 0.9%

Shares of ABBV opened at $218.05 on Friday. The company’s fifty day simple moving average is $225.87 and its 200-day simple moving average is $216.99. The company has a market cap of $385.38 billion, a P/E ratio of 165.19, a P/E/G ratio of 0.88 and a beta of 0.36. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s payout ratio is 524.24%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.